Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationDepreciation & Amortization (IS)LeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessReceivables - NetReceivables - Other
Ratios

Amylyx Pharmaceuticals (AMLX) Long-Term Debt Issuances (2021 - 2025)

Amylyx Pharmaceuticals has reported Long-Term Debt Issuances over the past 2 years, most recently at -$375000.0 for Q4 2025.

  • Quarterly results put Long-Term Debt Issuances at -$375000.0 for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $256.3 million (changed N/A YoY), and the annual figure for FY2025 was $256.3 million, changed.
  • Long-Term Debt Issuances for Q4 2025 was -$375000.0 at Amylyx Pharmaceuticals, down from $191.1 million in the prior quarter.
  • Over the last five years, Long-Term Debt Issuances for AMLX hit a ceiling of $191.1 million in Q3 2025 and a floor of -$375000.0 in Q4 2025.